Skip to content

Compounds · Metabolic & weight · Treatment of obesity and type 2 diabetes

Survodutide (BI 456906)

Full protocol

BI 456906, BI456906, Survodutide

A dual glucagon/GLP-1 receptor agonist (BI 456906) from Boehringer Ingelheim and Zealand Pharma. It combines glucagon-driven energy expenditure with GLP-1-driven appetite suppression for weight management and metabolic dysfunction–associated steatohepatitis.

0.3 → 4.8 mg weekly, titrated

Research score 85/100. Reference only, not a prescription.

  • Appetite Suppression
  • Blood Sugar Control
  • Metabolic Enhancement
  • GLP-1 Agonist
  • Weight Loss
US status
Investigational
Approval
Phase 2 Clinical Trial
Evidence
Phase 3 trials ongoing (SYNCHRONIZE). Strong weight loss and liver fat reduction data.
Research score
85 / 100
Indication
Investigational - Type 2 Diabetes Mellitus
Origin
Germany
Source category
Digestive System
Status group
Investigational

Mechanism

GLP-1 receptor activation raises glucose-dependent insulin release, cuts glucagon, slows gastric emptying, and promotes satiety via the hypothalamus; glucagon receptor activation adds energy expenditure and fat oxidation through liver glucose production and thermogenesis; structural modifications extend its half-life.

Safety file

GI effects such as nausea, diarrhea, and vomiting are common and dose-related; some trials saw higher discontinuation due to GI issues.

  • Nausea
  • Vomiting
  • Diarrhea
  • Decreased appetite
  • Injection site reactions

Reconstitution

Concentration by vial size and water volume
Vial1 mL water2 mL water
10 mg10 mg/mL5 mg/mL
  1. Use bacteriostatic water as the diluent.
  2. Add the water slowly, letting it run down the inside wall of the vial rather than onto the powder.
  3. Swirl gently to mix, then leave it to dissolve. Do not shake.
  4. Give it a few minutes. The finished solution should be clear and colourless.

Full mixing method

Protocol

Route: Subcutaneous

Standard titration (once weekly, subcutaneous)

  • Start at 0.3 mg once weekly and step up toward a working dose; the phase 2 trial escalated over 20 weeks
  • The phase 2 obesity trial topped out at 4.8 mg weekly; phase 3 (SYNCHRONIZE) goes up to 6 mg
  • Effects become noticeably stronger from 1.8 mg upward

Where most people land

  • 1.8 mg to 4.8 mg weekly is the working range
  • Do not skip steps; the glucagon and GLP-1 combination makes a fast ramp rough on the gut

Dosing detail

  • Start at 0.3 mg. This is a tolerance dose; real weight effect kicks in around 1.8 mg.
  • Step up gradually; the phase 2 trial took 20 weeks to reach the top dose.
  • Phase 2 went up to 4.8 mg weekly. Stay at the lowest dose that keeps you progressing.
  • One consistent day per week.

Duration

  • Titrate over roughly 4 months, then maintain. A plateau after 12 to 16 weeks at your target dose is normal, not failure.

Notes

  • A GLP-1 / glucagon dual agonist studied heavily for weight and metabolic effects.
  • Inject subcutaneously, rotate sites.
  • Nausea and fullness early on, easing as the body adjusts.

Storage and handling

  • Keep the powdered (lyophilized) vial in a cool, dark place. Refrigerate it for longer-term storage before mixing.
  • Once reconstituted and refrigerated at 2–8 °C away from light, use the vial within 28 days.
  • Do not freeze a reconstituted vial, and keep it away from heat and sunlight.
  • If the solution turns cloudy, develops floating particles, or shows any other sign of degradation, stop using that vial.

Storage rules and when to discard